ImmunoScape key facts
as of Oct 2026- Developer of an immune profiling system and analytical tools designed to support immunotherapy clinical development.
- ImmunoScape is valued at approximately $80.8M as of Oct 2026 (last reported valuation).
- It has raised $60.4M; the latest was Angel (individual) ($33.3M) in Mar 2026.
- Notable investors include EDBI, Johnson & Johnson Innovation - JLABS, The University of Tokyo Edge Capital, Leonardo DiCaprio, Accelerate Technologies — 9 tracked in total.
- Status: Privately Held (backing).
ImmunoScape's last reported valuation, Jun 2025. Nothing priced has surfaced since.
- ·Watch ImmunoScape: the Monday email on marks, rounds and moves
ImmunoScape funding rounds
No funding rounds for ImmunoScape are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
ImmunoScape valuation
ImmunoScape's last reported valuation was $80.8 million in Jun 2025. No priced round, secondary trade or fund mark has surfaced since.
ImmunoScape investors
9 investors are on record for ImmunoScape, including EDBI, Johnson & Johnson Innovation - JLABS, The University of Tokyo Edge Capital and Leonardo DiCaprio.
About ImmunoScape
Developer of an immune profiling system and analytical tools designed to support immunotherapy clinical development. The company's tools offer immune cell profiling technologies, antigen-specific T-cell identification, and an online analytical pipeline, enabling companies to gain valuable information on the efficacy and safety of immunotherapies across the research, development, and clinical phases.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2016
- Employees
- 23
- Website
- immunoscape.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.